US 12,304,969 B2
Factor XI A2 domain-binding antibodies and methods of use thereof
Dan Chalothorn, New York, NY (US); Lori C. Morton, Chappaqua, NY (US); and KehDih Lai, Yardley, PA (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Oct. 21, 2022, as Appl. No. 18/048,644.
Claims priority of provisional application 63/270,629, filed on Oct. 22, 2021.
Prior Publication US 2023/0131338 A1, Apr. 27, 2023
Int. Cl. C07K 16/36 (2006.01); A61P 7/02 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/36 (2013.01) [A61P 7/02 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. An isolated antibody, or antigen-binding fragment thereof, that binds to the apple 2 (A2) domain of coagulation factor XI (FXI), wherein the antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (HCVR) comprising a heavy chain complementarity determining region (HCDR) 1, HCDR2, and HCDR3, and a light chain variable region (LCVR) comprising a light chain complementarity determining region (LCDR) 1, LCDR2, and LCDR3, wherein
(a) the HCDR1 comprises the amino acid sequence of SEQ ID NO: 5;
(b) the HCDR2 comprises the amino acid sequence of SEQ ID NO: 7;
(c) the HCDR3 comprises the amino acid sequence of SEQ ID NO: 9;
(d) the LCDR1 comprises the amino acid sequence of SEQ ID NO: 15;
(e) the LCDR2 comprises the amino acid sequence of SEQ ID NO: 17; and
(f) the LCDR3 comprises the amino acid sequence of SEQ ID NO: 19; or
wherein
(a) the HCDR1 comprises the amino acid sequence of SEQ ID NO: 33;
(b) the HCDR2 comprises the amino acid sequence of SEQ ID NO: 35;
(c) the HCDR3 comprises the amino acid sequence of SEQ ID NO: 37;
(d) the LCDR1 comprises the amino acid sequence of SEQ ID NO: 15;
(e) the LCDR2 comprises the amino acid sequence of SEQ ID NO: 17; and
(f) the LCDR3 comprises the amino acid sequence of SEQ ID NO: 19.